ESSA Pharma Inc (EPIX)
6.40
+0.08
(+1.27%)
USD |
NASDAQ |
Apr 22, 16:00
6.64
+0.24
(+3.75%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 283.12M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 130.2% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 2.012 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.40% |
Profile
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
URL | https://www.essapharma.com |
Investor Relations URL | https://investors.essapharma.com/ |
HQ State/Province | British Columbia |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 13, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
URL | https://www.essapharma.com |
Investor Relations URL | https://investors.essapharma.com/ |
HQ State/Province | British Columbia |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 09, 2024 (est.) |
Last Earnings Release | Feb. 13, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |